Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab vs Corticosteroids in Pediatric Ulcerative Colitis
NCT04999228Phase 4Recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Nov 2021
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of infliximab in ulcerative colitis (UC), sponsored by Children's Hospital of Fudan University. Primary endpoint: Mucosal healing rate at 12 weeks. Started Nov 2021; status: recruiting.
02
Drugs
infliximab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04999228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999228.